Delivery Order SPE2DB25D3202-SPE2DB25FTBFQ
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on August 15, 2025, with a ceiling value of $8,246.40 and an ultimate completion date of August 18, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 5 mg/0.5 ml pens valued at $3,647.57. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $6,685.83 delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract utilized firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $20,902.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This contract, which carries an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order was competitively awarded without set-aside...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBFQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,242.81 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical supply requirements, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This particular order for Zepbound, a diabetes medication, exemplifies the company's role in supporting Defense Health Agency procurement needs through the DLA's global pharmaceutical supply network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 8/27/25 |